<<

Metrochem API Private Limited

APIs USDMF / CEP Numbers Submission Date Status Written Confirmation

Acotiamide

Alogliptin Benzoate

Antazoline HCL CEP 2020-060 10 February,2020

Antazoline Phosphate USDMF 34330 1 January,2020

Apixaban USDMF 35518 30 December,2020

Apremilast

Azilsartan

Baloxavir Marboxil Product Under Validation

Bempedoic Acid

Bepotastine Besilate

Bilastine

Canagliflozin

Cenobamate

Cinitapride

Clopidogrel Bisulfate Form I USDMF 34334 5 February,2020 Indian CDSCO WC-0493

Clopidogrel Bisulfate Form II USDMF 34334 5 February,2020 Indian CDSCO WC-0493

Crisaborole

Dabigatran

Dapaglifloin Amorphous

Dapagliflozin

Dexketoprofen Trometamol USDMF 34732 21 March,2020 Indian CDSCO WC-0493

Dexlansoprazole USDMF 34971 29 September,2020

Dexrabeprazole

Dimethindene Maleate CEP 2021-080 6 February,2021

Edoxaban

Efinaconazole

Elagolix

Elobixibat Product Under Validation

Eltrombopag

Empagliflozin USDMF 35345 31 October,2020 Indian CDSCO WC-0493

Empagliflozin Amorphous

Ertugliflozin

Esomeprazole Dihydrate USDMF 35519 ; CEP 2021-022 29 December,2020 ; 28 December 2020

Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Metrochem API Private Limited

APIs USDMF / CEP Numbers Submission Date Status Written Confirmation

Esomeprazole Magnesium Trihydrate USDMF 35400 ; CEP 2020-386 28 November,2020 ; 21 November,2020

Esomeprazole Sodium CEP 2020-214 30 June,2020

Etoricoxib USDMF 34537 22 February,2020 Indian CDSCO WC-0493

Febuxostat USDMF 35578 13 February,2021

Febuxostat Form A USDMF 35797 27 March,2021

Fingolimod

Fosravuconazole Product Under Validation

Gabapentin

Garenoxacin

Ilaprazole

Imeglimin Hydrochloride

Ipragliflozin

Isavuconazonium Sulphate

Itraconazole Indian CDSCO WC-0493

Ivabradine Product Under Validation

Lacosamide

Lansoprazole USDMF 35485 ; CEP 2021-009 22 December,2020 ; 25 December,2020

Lasmiditan

Levocetirizine Di Hcl USDMF 34731 12 May,2020 Indian CDSCO WC-0493

Levomilnacipran

Loxoprofen Sodium Product Under Validation

Lurasidone Hcl USDMF 34756 14 July,2020

Migalastat

Mirabegron

Mirabegron Amorphous

Montelukast Sodium

Omecamtiv Marcabil Product Under Validation

Omeprazole USDMF 34759 ; CEP 2020-182 3 June,2020 ; 8 June,2020 Indian CDSCO WC-0493

Omeprazole Magnesium USDMF 35390 ; CEP 2020-380 20 November,2020 ; 12 November,2020

Omeprazole Sodium CEP 2020-372 10 November,2020

Oseltamavir Phosphate

Oxcarbazepine

Oxiconazole Nitrate USDMF 34173 23 September,2019 Indian CDSCO WC-0493

Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Metrochem API Private Limited

APIs USDMF / CEP Numbers Submission Date Status Written Confirmation

Ozenoxacin USDMF 35487 26 December,2020

Pantoprazole Magnesium USDMF 35516 25 March,2021

Pantoprazole Sodium Sesquihydrate USDMF 35577 31 March,2021

Pirfenidone

Ponesimod

Posaconazole USDMF 35517 11 January,2021

Prucalopride Succinate USDMF 34970 21 August,2020

Rabeprazole Sodium USDMF 35344 27 November,2020

Ranolazine

Relugolix

Remogliflozin

Saxagliptin

Silodosin USDMF 34538 3 March,2020 Indian CDSCO WC-0493

Silodosin Beta Form

Siponimod

S-Pantoprazole

Stiripentol Product Under Validation

Tafenoquine Succinate Product Under Validation

Tedizolid Phosphate USDMF 35515 20 February,2021

Teneligliptin USDMF 35576 26 March,2021

Ticagrelor

Tofacitinib

Topiroxostat

Tranexamic Acid Product Under Validation

Trelagliptin

Upadacitinib Tartrate Product Under Validation

Vibegron

Vigabatrin

Vilanterol

Vildagliptin

Vonoprazan Fumarate USDMF 35150 31 August,2020

Vortioxetine Product Under Validation

Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer.